Creative License? A recent court ruling could put a damper on licensing.
Opinions expressed by Entrepreneur contributors are their own.
A portfolio licensing agreement between bio-tech companies MedImmune and Genentech was going well--that is, until it went bad.
When MedImmune took a patent dispute with Genentech to court, Genentech argued that MedImmune didn't have any legal footing to do so since it hadn't terminated its patent license. A lower court sided with Genentech, but the Supreme Court ruled that MedImmune didn't have to breach or terminate its patent license to take its complaint before a judge.
Continue reading this article — and all of our other premium content with Entrepreneur+
Join the internet’s leading entrepreneur community! With your subscription you’ll get:
- Access to all of our premium content and an ad-free experience
- A complimentary subscription to Entrepreneur Magazine
- Four free e-books a year and 20% off everything from our bookstore
- Exclusive events with business celebrities and successful entrepreneurs